Abigail Laura Jackson

Abigail Laura Jackson serves as an Assistant Professor in the Department of Cellular and Molecular Medicine at the University of Copenhagen's Faculty of Health and Medical Sciences. She is a core member of the Morphogenesis and Differentiation Program and the Human Stem Cell Biology Laboratory (Semb lab), where she investigates embryonic organ development with emphasis on pancreatic formation and cellular organization.

Her educational background includes a PhD in Developmental Biology from King's College London (2008-2012), a first-class Master of Biology (Mbiol) from the University of Bath (2004-2008), and an academic placement at the London School of Hygiene and Tropical Medicine (2007).

• PhD: Developmental Biology, King's College London (2008-2012)
• Mbiol (1st class): University of Bath (2004-2008)
• Academic Placement: London School of Hygiene and Tropical Medicine (2007)

Dr. Jackson's research centers on cellular polarization mechanisms during embryonic pancreas development. She investigates how spatial organization of pancreatic cells governs maturation into insulin-producing beta cells, with disruptions directly linked to diabetes pathogenesis. Her work bridges fundamental developmental biology and regenerative medicine, aiming to develop stem cell-based diabetes therapies through precise differentiation protocols targeting cell polarity pathways.

Analysis of her publication record reveals sustained focus on pancreatic progenitor dynamics, with her 2018 Nature paper establishing integrin mechanosignaling as a critical fate determinant and her 2023 Cell Stem Cell study identifying early insulin hypersecretion in MODY3 patient cells. These works demonstrate translational progression from basic developmental mechanisms to disease modeling, consistently emphasizing cellular organization as the cornerstone of functional pancreatic tissue.

Dr. Jackson maintains active collaboration within the Semb lab and international consortia, evidenced by multi-institutional publications and significant research impact (178 Scopus citations for her 2018 Nature paper). Her work has generated substantial scientific attention including news coverage, social media dissemination, and patent references, reflecting its clinical relevance to diabetes therapeutics.